Mahalakshmi Radhakrishnan
Director/Board Member at ALTO NEUROSCIENCE, INC.
Net worth: - $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Deborah Rathjen | M | - | 7 years | |
Amit Etkin | M | 48 | 5 years | |
Nicholas Smith | M | 36 | 3 years | |
Natalie Yivgi-Ohana | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Christopher Viehbacher | M | 64 | 2 years | |
Wei Wu | M | 42 | 5 years | |
Christopher Cox | M | 45 | 2 years | |
Nestle Frank | M | - | 8 years | |
John E. Curran | M | - | 6 years | |
Ephraim Aharonson | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Erin McQuade | F | 50 | 1 years | |
Susan Langer | F | - | 1 years | |
Monish Patolawala | M | 54 | - | |
Maria Freire | M | 69 | 3 years | |
Priya Singhal | M | 56 | 3 years | |
Jessica Powell | F | 50 | 2 years | |
Alexandra Roger | F | - | 8 years | |
Alfred Sandrock | M | 67 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | 24 years |
Andrew Dreyfus | M | 65 | 1 years | |
Nicole Murphy | F | - | 9 years | |
Christopher Lowe | M | 56 | 7 years | |
Uriel Halavee | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Gwill York | F | 67 | 3 years | |
David Wurzer | M | 65 | 6 years | |
Rachid Izzar | M | - | 3 years | |
Chuck Triano | M | - | 1 years | |
Adam Savitz | M | 59 | 3 years | |
Jane Grogan | M | 57 | 1 years | |
Fadi Abdel | M | 46 | 3 years | |
Melissa Berman | F | 45 | 1 years | |
Aida Habtezion | M | - |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | 2 years |
George Addona | M | - |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | 2 years |
Michael McDonnell | M | 60 | 4 years | |
Adam Keeney | M | - | 1 years | |
Thomas Insel | M | 72 | - | |
Zeev Milbauer | M | 69 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Po Yu Chen | M | 44 | 2 years | |
Lori M. Reilly | F | - |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | 2 years |
Dietmar Berger | M | - | 5 years | |
Kelly Huang | M | 55 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Mario David Saltarelli | M | 63 | 6 years | |
John Cox | M | 61 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 5 years |
Shmuel Cabilly | M | 74 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | - |
Iris Löw-Friedrich | M | 63 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | 5 years |
Mikael Dolsten | M | 65 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Jan Lundberg | M | 70 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Steven Gilman | M | 71 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Christy Shaffer | M | 66 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Patricia A. Seymour | M | - |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robin Hutchison | M | 68 | 10 years | |
Michel Vounatsos | M | 62 | 6 years | |
Stelios Papadopoulos | M | 75 | 15 years | |
William Young | M | 79 | 11 years | |
Diane D. Souza | F | 71 | 8 years | |
Chirfi Guindo | M | 58 | 5 years | |
Trevor Anthony Mill | M | 53 | 9 years | |
Samantha Truex | F | - | 8 years | |
Bonnie Bassler | M | 61 | 2 years | |
Gregory Gubitz | M | 66 | 5 years | |
Caroline Luscombe | F | 64 | 2 years | |
Caroline Dircks | M | - | 2 years | |
Judith F. Dalling | F | 69 | 3 years | |
Thomas C. Südhof | M | 68 | 8 years | |
J. Hutchison | M | 68 | 9 years | |
Douglas Kerr | M | 57 | 2 years | |
H. Christian Fibiger | M | 80 | 7 years | |
Nancy L. Leaming | F | 76 | 14 years | |
Ronald Erickson | M | 80 | 7 years | |
Emmanuel Babeau | M | 57 | 2 years | |
Nancy E. Stagliano | M | 57 | 2 years | |
Brian Posner | M | 62 | 14 years | |
Jeffrey Capello | M | 69 | 3 years | |
Terry Pearson | M | 78 | 9 years | |
William Jones | M | 68 | 2 years | |
Robert W. Pangia | M | 72 | 24 years | |
Robert Castaigne | M | 78 | 18 years | |
Lynn Schenk | F | 79 | 25 years | |
Bernard Charlès | M | 66 | - | |
Muriel Bardet | F | - | 16 years | |
Alexander Denner | M | 54 | 14 years | |
Klaus Pohle | M | 86 | 12 years | |
Richard Mulligan | M | 69 | 14 years | |
Melanie Lee | M | 65 | 5 years | |
Bernard Ravina | M | 56 | 4 years | |
Raymond Pawlicki | M | 63 | 6 years | |
Keith Regnante | M | 54 | 14 years | |
Philip Ma | M | 59 | 2 years | |
Adrian Gottschalk | M | 49 | 2 years | |
Daniel Karp | M | 46 | 2 years | |
Mark Hernon | M | - | 4 years | |
Jeffrey D. Bornstein | M | - | 3 years | |
Paul McKenzie | M | 58 | 3 years | |
Olivier Danos | M | 66 | 3 years | |
Steven Holtzman | M | 70 | 5 years | |
Glenn F. Pierce | M | 68 | 5 years | |
Matthew P. Ottmer | M | 53 | 16 years | |
Richard Ransohoff | M | - | 3 years | |
Wildon Farwell | M | 49 | - | |
Douglas Williams | M | 66 | 4 years | |
Donald R. Johns | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 81 | 81.00% |
France | 13 | 13.00% |
Israel | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mahalakshmi Radhakrishnan
- Personal Network